Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz, Taiwan’s TLC Ink Commercialization Deal For AmBisome Generic In U.S., EU

This article was originally published in PharmAsia News

Executive Summary

Sandoz will commercialize TLC’s liposomal amphotericin B product, a generic of Gilead’s AmBisome, in the U.S. and EU.

You may also be interested in...



Taiwan Liposome Company Nearing IPO After Round Of Financing

HONG KONG - A cash injection from a U.S. venture capital firm may help a Taiwanese developer of drug delivery systems better compete on a global scale as it moves towards an initial public offering

Taiwan Liposome Seeks To Teach Old Drugs New Tricks In China And Markets Far From Home

Taiwan Liposome Co. Ltd. has the funds and team to reach outside of its base in Taiwan to turn old drugs into new products and is looking for opportunities at Asia-specific product applications.

Emerging Company In An Emerging Market: Generon Sees Quality And Price As Litmus Test

Generon in Shanghai was founded by former Hutchison MediPharma employees to target a niche market between expensive import drugs and lower quality domestic products.

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel